全文获取类型
收费全文 | 784篇 |
免费 | 16篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 26篇 |
妇产科学 | 9篇 |
基础医学 | 26篇 |
口腔科学 | 3篇 |
临床医学 | 227篇 |
内科学 | 207篇 |
皮肤病学 | 27篇 |
神经病学 | 38篇 |
特种医学 | 2篇 |
外科学 | 71篇 |
综合类 | 16篇 |
一般理论 | 1篇 |
预防医学 | 97篇 |
药学 | 38篇 |
肿瘤学 | 19篇 |
出版年
2024年 | 2篇 |
2022年 | 2篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 32篇 |
2014年 | 29篇 |
2013年 | 19篇 |
2012年 | 41篇 |
2011年 | 47篇 |
2010年 | 26篇 |
2009年 | 47篇 |
2008年 | 27篇 |
2007年 | 43篇 |
2006年 | 62篇 |
2005年 | 30篇 |
2004年 | 23篇 |
2003年 | 8篇 |
2002年 | 12篇 |
2001年 | 33篇 |
2000年 | 18篇 |
1999年 | 30篇 |
1998年 | 37篇 |
1997年 | 18篇 |
1996年 | 27篇 |
1995年 | 27篇 |
1994年 | 27篇 |
1993年 | 16篇 |
1992年 | 8篇 |
1991年 | 9篇 |
1990年 | 7篇 |
1989年 | 5篇 |
1988年 | 8篇 |
1987年 | 10篇 |
1986年 | 7篇 |
1985年 | 6篇 |
1984年 | 5篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1978年 | 5篇 |
1963年 | 2篇 |
1961年 | 2篇 |
1960年 | 2篇 |
1959年 | 3篇 |
1958年 | 2篇 |
1947年 | 2篇 |
1941年 | 3篇 |
排序方式: 共有808条查询结果,搜索用时 15 毫秒
21.
22.
FOX K.; POOL J.; VOS $$$; LUBSEN J.; ON BEHALF OF THE ROCKET-STUDY GROUP 《European heart journal》1991,12(8):1283-1287
This study was designed to examine the effects of nisoldipine(relative to placebo), a new dihydropyridine calcium entry blockingagent, in the treatment of silent ischaemia in conventionaldoses. A total of 409 patients with proven coronary artery diseasewere screened and of this 64 had at least six episodes or atotal duration of 30 mm of ST segment depression (1 mm lastingat least 1 min) over 48 h. Fifty-two patients ultimately completeda randomized double-blind cross-over study comparing nisoldipine5 mg twice a day, nisoldipine 10 mg daily and placebo. There was a reduction in the ST segment integral and numberof episodes of ST segment depression when compared to placeboon treatment with nisoldipine 5 mg twice a day and nisoldipine10 mg daily. However, the confidence limits were wide and crossedthe no-treatment effect line. In addition, the nisoldipine dosesneither affected the circadian distribution of ischaemic episodesnor caused an alteration of the workload achieved either atpeak exercise or at 1 mm ST segment depression measured 24 hafter nidoldipine 10 mg or 12 h after nisoldipine 5 mg. We conclude that frequent silent ischaemia in patients withproven coronary artery disease is relatively uncommon, it accountsfor approximately 16% of patients with positive exercise. Inthese patients nisoldipine, given as 5mg twice a day and 10mg daily, showed no significant therapeutic effects, eitheron the frequency or severity of silent ischaemia. New formulationsof slow release nisoldipine are consequently being developedso that a fuller 24 h therapeutic profile may be obtained. 相似文献
23.
BADANO L.; BERTOLI D.; ASTENGO D.; CARRATINO L.; DEGAETANO G.; PASSERONE G. C.; CAMERIERI A.; GRAMENZI S.; MAGAJA O.; FAZZINI L.; PAPAGNA D.; BIANCHI F.; BARBERIS L.; LUCATTI A.; ON BEHALF OF THE VALVE PROSTHESES LIGURIAN COOPERATIVE DOPPLER STUDY 《European heart journal》1993,14(12):1602-1609
Doppler echocardiographic characteristics of normally functioningAllcarbon prostheses were studied in 149 consecutive patientswith 157 valves in the mitral (n=73) and aortic (n=84) positionswhose function was considered normal by clinical and echocardiographicevaluation. In the mitral position, the mean gradient and theeffective mitral orifice area were not significantly differentin either the 25-mm or the 31-mm size valves (from 5±1to 4±1 mmHg and from 2.2±0.6 to 2.8±0.9cm2, respectively; P=ns for both). Conversely, peak gradientwas significantly and inversely correlated to actual orificearea (r=0.70; P<0.0006), decreasing from 15±3mmHg in the 25-mm size valve to 9±1 mmHg in the 31-mmsize. In the aortic position, the mean gradient was 29±8 mmHgin the 19-mm size valve; it decreased to 8±2 mmHg inthe 29-mm size. Effective prosthetic aortic valve area, calculatedusing the continuity equation, ranged between 0.9±0.1cm2 for the 19-mm size valve to 4.1±0.7 cm2 for the 29-mmsize. By analysis of variance, effective prosthetic aortic valvearea differentiated various valve sizes (F=25.3; P<0.0001)better than peak (F=5.34; P=0.012) or mean (F=4.34; P=0.0052)gradients alone, and it correlated better with actual orificearea (r=0.89, r=0.70 and r=0.65, respectively).This study provides the normal range for Doppler haemodynamiccharacteristics of the various sizes of the Allcarbon valvein the mitral and aortic positions so that prosthetic malfunctioncan be identified. 相似文献
24.
COHEN M.; PARRY G.; ADAMS P.C.; XIONG J.; CHAMBERLAIN D.; WIECZOREK I.; FOX K. A. A.; KRONMAL R.; FUSTER V.; THE ANTITHROMBOTIC THERAPY IN ACUTE CORONARY SYNDROMES RESEARCH GROUP 《European heart journal》1994,15(9):1196-1203
The aim of this trial was to compare the efficacy of combinationantithrombotic therapy with a prostacyclin-sparing aspirin plusanticoagulation versus conventional aspirin plus anticoagulation,when added to antianginal therapy, in patients with unstableangina or non-Q wave myocardial infarction already being treatedwith aspirin. In a double-blind (for the aspirin) study, 144prior aspirin users were randomized; 72 patients received controiled-release,prostacyclin-sparing aspirin 75 mg daily plus anticoagulation(intravenous heparin followed by warfarin to maintain the internationalnormalized ratio at 23), and 72 patients received conventionalaspirin 75 mg daily plus the same anticoagulation. Controlled-releaseaspirin was formulated to preserve endothelial cell prostacyclinsynthesis. Trial therapy was begun by 13.2 ± 12.3 h ofqualifying pain, and continued for 12 weeks. The frequency of recurrent angina with electrocardiographicchanges, myocardial infarction, or death, was analysed by intentionto treat. At 12 weeks, events were 相似文献
25.
YUKIHIKO KAWASAKI MITSUAKI HOSOYA SEIJI YASUMURA TETSUYA OHIRA HIROAKI SATOH HITOSHI SUZUKI AKIRA SAKAI AKIRA OHTSURU ATSUSHI TAKAHASHI KOTARO OZASA GEN KOBASHI KENJI KAMIYA SHUNICHI YAMASHITA MASAFUMI ABE THE FUKUSHIMA HEALTH MANAGEMENT SURVEY GROUP 《Fukushima journal of medical science》2015,61(2):101-110
26.
Aznar JA Marco A Jiménez-Yuste V Fernández-Fontecha E Pérez R Soto I Parra R Moreno M Mingot ME Moret A;ON BEHALF OF THE SPANISH HAEMOPHILIA EPIDEMIOLOGICAL STUDY WORKING GROUP 《Haemophilia》2012,18(5):738-742
Summary. On‐demand therapy enables stopping haemorrhages rapidly, reducing joint pain and restoring joint mobility, but does not prevent the beginning and subsequent development of haemophilic arthropathy. The main objective of this study was to identify the clinical and orthopaedic status of severe haemophilic patients with bleeding phenotype receiving on‐demand treatment in Spain. We conducted an epidemiological, observational, retrospective study, recruiting 167 patients from 36 centres (92% of them with haemophilia A), median age at enrolment of 35 years. Forty per cent of the patients received a combination of on‐demand and short‐term prophylaxis regimen; the rest was under on‐demand treatment. One hundred and forty‐five patients (87%) reported at least one bleeding episode and 22 (13%) of the biologically severe patients had no bleeding phenotype. Seventy‐one per cent of the studied population presented established haemophilic arthropathy, reaching 80% if we exclude patients without bleeding phenotype. Forty‐three per cent of these patients had one or two joints affected, 28% of them had three or four affected joints, 20% reported five or six affected joints and 9% more than six injured joints. An increase in established haemophilic arthropathy with age was observed. Forty‐six patients underwent orthopaedic surgery at least once. These data show that on‐demand therapy is not effective in preventing the development of haemophilic arthropathy in severe haemophilic population with bleeding phenotype. Therefore, we suggest that the optimal treatment in these patients should be based on prophylaxis. We recommend analysing the reasons for ending prophylaxis, in case its reinstatement should be necessary. 相似文献
27.
Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study 总被引:16,自引:0,他引:16
P. DEFAYE F. DOURNAUX E. MOUTON for the AIDA MULTICHNTER STUDY GROUP. 《Pacing and clinical electrophysiology : PACE》1998,21(1):250-255
The confirmation of the occurrence of supraventricular arrhythmias (SVAs) is possible only if a surface electrocardiogram (ECG) is recorded during an episode, or if SVAs occur during 24 h ambulatory monitoring (Holter). The automatic interpretation of memory functions in DDD pacemakers may be useful in this diagnostic task over longer periods of follow up. This hypothesis was tested in 384 men and 233 women (mean age = 70 ± 11 years) who had received Chorus 6034/6035, 6234 or 7034 pacemakers (ELA Medical, Montrouge, France) with fall-back function in case of sustained SVAs. The Automatic Interpretation for Diagnostic Assistance (AIDA) algorithm included in these pacemakers was compared with 24 h Holters recorded simultaneously (DI) and with the clinical history of symptoms consistent with SVAs up to 28 days of follow up (D28). Indications for pacing were atrioventricular block (AVB) in 269 patients, sinus node dysfunction (SND) in 248, and AVB + SND in 100. SVAs were documented before implant in 199 patients (32%). Among the 617 patients included at D1. 76 (12.4%) developed at least one SVA episode, lasting between 1 min and 24 hours, simultaneously recorded on Holter and by AIDA with a 93.8% sensitivity and 94.2% specificity. Data from 354 patients were available for analysis at D28. AIDA diagnosed SVAs in 179 patients (50.6%), 104 of whom (65%) had remained asymptomatic and 117 of whom (65%) had had no SVA documented before implant. Among the 354 patients, AIDA diagnosed SVAs in 76 (21%) asymptomatic patients who had no known SVA before implant. The prevalence of SVA in our AVB population was higher than reported in previous studies: 89 patients (56.3%) with AVB had SVAs versus 90 patients (45.9%) with other diagnoses (p=0.55). Furthermore atrial pacing was associated with fewer SVAs. These first clinical results of the AIDA study demonstrate that the memory functions of Chorus pacemakers and the AIDA software are reliable to analyze the prevalence of SVA at 1 month of follow-up. From a clinical point of view, AIDA is a valuable tool to evaluate the efficacy of antiarrhythmic therapy, particularly as it pertains to the prevention of stroke due to atrial fibrillation. 相似文献
28.
GARY W. SMALL LON S. SCHNEIDER S. H. HAMILTON ALEXANDER BYSTRITSKY BARNETT S. MEYERS CHARLES B. NEMEROFF FLUOXETINE COLLABORATIVE STUDY GROUP 《International journal of geriatric psychiatry》1996,11(12):1089-1095
We studied differences in outcome and characteristics among 29 clinical sites of a multisite, double-blind antidepressant trial for geriatric depression. Six hundred and seventy-one outpatients aged 60 years or older (mean±SD=67.7±5.7) met DSM-III-R criteria for unipolar major depression, had baseline 17-item Hamilton Depression Rating Scale (HAMD17) scores ≥16 and were randomized to fluoxetine (20 mg daily) or placebo. Effect sizes (ESs, expressed as mean differences between effects divided by the pooled standard deviation of the differences) were calculated for each site using selected outcome measures. ES ranged from 1.84 (favoring fluoxetine) to −0.91 (favoring placebo) for incidence of remitters (endpoint HAMD17 total score of ≤8). A large, positive ES favoring fluoxetine for remission rates (ES≥0.65) was found at only six sites, moderate ES (0.35–0.64) at eight and small ES (0–0.34) at seven; ES favored placebo (<0) at eight of 29 sites. Private clinics showed an overall HAMD17 ES for change scores more than twice that of university sites. These results suggest that individual practitioners may have vastly different clinical experiences in large, multisite trials for geriatric depression. Interrater reliability, subject selection, recruitment, inadequate or fixed dosing, few patients per site, brief study duration, heterogeneity of geriatric depression, financial incentive and characteristics of individual sites may contribute to response variability. 相似文献
29.
30.